Navigation Links
US CNS Disorders Drug Pipeline Insight 2014
Date:8/29/2014

DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering.

The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

Key Topics Covered:

1. Introduction to Central Nervous System (CNS) Disorder

2. US Central Nervous System (CNS) Disorder Market Overview

3. US Central Nervous System (CNS) Disorder Incidence by Disease

4. US Central Nervous System (CNS) Disorder Market Dynamics

5. US Multiple CNS Disorder Drug Pipeline by Phase & Company

6. US Alzheimer's Disease Drug Pipeline by Phase & Company

7. US Multiple Sclerosis Drug Pipeline by Phase & Company

8. US Parkinson's Disease Drug Pipeline by Phase & Company

9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company

10. US Epilepsy Drug Pipeline by Phase & Company

11. US Migraine Drug Pipeline by Phase & Company

12. US Huntington's Disease Drug Pipeline by Phase & Company

13. US Neuropathic Pain Clinical Pipeline by Phase & Company

14. US Schizophrenia Clinical Trial Insight by Phase & Company

15. US Sleep Disorders Drug Pipeline by Phase & Company

16. Competitive Landscape

Companies Mentioned:

  • Alkermes
  • Allergan
  • AstraZeneca
  • Biogen Idec
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/vtvc8r/us_cns_disorders

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
2. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
3. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
4. Elsevier and the Society for Vascular Surgery Announce Forthcoming Launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
5. Global Anxiety Disorders Industry
6. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Global Market for Neurodegenerative Disorder Treatments to Reach $23.5 billion in 2017, Weakness Disorders Treatments Outpace Progressive Ataxia Treatments
8. OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders
9. Easy on the Stomach: ALCAT Worldwide Sponsors Successful Conference on Gut, Brain & Autoimmune Disorders
10. Elbit Imaging Ltd. Announces InSightecs ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
11. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... PLANO, Texas , April 20, 2017  Vivify ... via mobile devices, has been awarded a very significant ... care via EMRs to continual care via digital health. ... of key intellectual property and further secures Vivify,s position ... Vivify, launched in 2009, was the first company to ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... TransDark is ... transition from one video to the next without having to set a single keyframe ... blasting transitions to enhance your video production. , TransDark features dynamic transitions that momentarily ...
(Date:4/29/2017)... Texas (PRWEB) , ... April 29, 2017 , ... ... to celebrate the profession and recognize the positive impact veterinarians have on animal ... (WVA) and the World Organization for Animal Health (OIE) choose a theme each ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... ... 28, 2017 , ... Getting enough sleep affects much more than energy – it also has ... without sleep can compromise motor reaction time, which can increase the risk of having a ... the following tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
Breaking Medicine News(10 mins):